Blog
About

  • Record: found
  • Abstract: found
  • Article: not found

Improved survival with vemurafenib in melanoma with BRAF V600E mutation.

Read this article at

ScienceOpenPublisherPMC
Bookmark
      There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

      Abstract

      Phase 1 and 2 clinical trials of the BRAF kinase inhibitor vemurafenib (PLX4032) have shown response rates of more than 50% in patients with metastatic melanoma with the BRAF V600E mutation.

      Related collections

      Author and article information

      Affiliations
      [1 ] Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA. chapmanp@mskcc.org
      Journal
      N. Engl. J. Med.
      The New England journal of medicine
      New England Journal of Medicine (NEJM/MMS)
      1533-4406
      0028-4793
      Jun 30 2011
      : 364
      : 26
      21639808
      10.1056/NEJMoa1103782
      3549296
      NIHMS431913

      Comments

      Comment on this article